Document Detail

Effects of eprosartan versus hydrochlorothiazide on markers of vascular oxidation and inflammation and blood pressure (renin-angiotensin system antagonists, oxidation, and inflammation).
MedLine Citation:
PMID:  11897210     Owner:  NLM     Status:  MEDLINE    
Antagonists of the renin-angiotensin system, such as angiotensin type 1 (AT(1)) receptor inhibitors and angiotensin-converting enzyme inhibitors, are becoming increasingly popular agents in treating patients with systemic hypertension and minimizing organ damage. In the present study, we compared the effects of eprosartan, an AT(1) receptor inhibitor, with the diuretic hydrochlorothiazide in a group of newly diagnosed hypertensive patients with multiple risk factors for atherosclerosis. The subjects were monitored and tested at 0 and 4 weeks to determine their individual effects on vascular and inflammatory markers. Although blood pressure reduction was comparable between the 2 agents, there were notable differences in their effects on markers of inflammation and oxidation. We observed a 28% reduction in neutrophil superoxide anion generating capacity, a 34% reduction in soluble monocyte chemotactic protein-1, and a 35% reduction in soluble vascular cell adhesion molecule with eprosartan therapy (all p <0.05 from the start of therapy). In addition, eprosartan showed further benefit in its ability to increase low-density lipoprotein oxidation lag time, suggesting an increased resistance to oxidation and/or modification of low-density lipoprotein. Although hydrochlorothiazide was effective in blood pressure reduction, there were no significant changes in any of the above parameters after 4 weeks of treatment. These findings suggest that eprosartan, an AT(1) receptor inhibitor, effectively reduces systemic blood pressure and, compared with hydrochlorothiazide, suggests additional benefits in the vasculature by inhibiting mechanisms of inflammation and oxidation.
Syed T Rahman; Wright B Lauten; Qamar A Khan; Sushant Navalkar; Sampath Parthasarathy; Bobby V Khan
Publication Detail:
Type:  Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  The American journal of cardiology     Volume:  89     ISSN:  0002-9149     ISO Abbreviation:  Am. J. Cardiol.     Publication Date:  2002 Mar 
Date Detail:
Created Date:  2002-03-18     Completed Date:  2002-04-02     Revised Date:  2007-11-14    
Medline Journal Info:
Nlm Unique ID:  0207277     Medline TA:  Am J Cardiol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  686-90     Citation Subset:  AIM; IM    
Emory University School of Medicine, Division of Cardiology, Atlanta, Georgia 30303, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Acrylates / therapeutic use*
Antihypertensive Agents / therapeutic use*
Blood Pressure / drug effects*
Chemokine CCL2 / genetics
Dose-Response Relationship, Drug
Gene Expression Regulation / drug effects
Hydrochlorothiazide / therapeutic use*
Hypertension / complications,  drug therapy
Imidazoles / therapeutic use*
Inflammation / complications,  drug therapy*
Lipoproteins, LDL / drug effects
Middle Aged
Muscle, Smooth, Vascular / drug effects
Oxidation-Reduction / drug effects*
Receptors, Angiotensin / antagonists & inhibitors*,  therapeutic use*
Renin-Angiotensin System / drug effects*
Treatment Outcome
Vascular Cell Adhesion Molecule-1 / drug effects
Grant Support
Reg. No./Substance:
0/Acrylates; 0/Antihypertensive Agents; 0/Chemokine CCL2; 0/Imidazoles; 0/Lipoproteins, LDL; 0/Receptors, Angiotensin; 0/Thiophenes; 0/Vascular Cell Adhesion Molecule-1; 133040-01-4/eprosartan; 58-93-5/Hydrochlorothiazide

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Differentiation between LQT1 and LQT2 patients and unaffected subjects using 24-hour electrocardiogr...
Next Document:  Risk stratification using a combination of cardiac troponin T and brain natriuretic peptide in patie...